Pharma Focus Europe

Initiation of First Patient Dosing in Phase 1/2 Clinical Trial Investigating SAR'514/IPH6401 for Relapsed/Refractory Multiple Myeloma

Wednesday, July 12, 2023

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has made an announcement regarding the initiation of a Phase 1/2 clinical trial sponsored by Sanofi (NCT05839626). This trial aims to assess the safety, pharmacokinetics, and preliminary efficacy of SAR'514 / IPH6401 in patients with relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA).

SAR'514 is a trifunctional anti-BCMA NKp46xCD16 NK cell engager developed using Sanofi's CROSSODILE® multi-functional platform. This platform utilizes the Cross-Over-Dual-Variable-Domain (CODV) format and targets the NK activating receptors NKp46 and CD16, optimizing NK cell activation based on Innate's ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.

Dr. Joyson Karakunnel, Chief Medical Officer at Innate Pharma, expressed satisfaction with the progress of the ANKET® platform and highlighted the potential of SAR'514 / IPH6401 to provide innovative treatment options for patients with RRMM or RRLCA. The engagement of NK cell effector functions against cancer cells could significantly benefit these patients.

Dr. Peter Adamson, Global Development Head, Oncology at Sanofi, expressed excitement about the collaboration with Innate Pharma and their shared goal of improving outcomes for patients with RRMM and RRLCA. The dosing of the first patient with SAR'514 / IPH6401 is an important milestone in their collaboration.

The initiation of the trial has triggered a milestone payment from Sanofi to Innate Pharma, as part of their previously announced research collaboration.

ANKET® is Innate's proprietary platform designed to develop next-generation, multi-specific natural killer (NK) cell engagers for certain types of cancer. This platform aims to induce synthetic immunity against cancer using versatile and purpose-built technology.

Under the research collaboration and license agreement between Innate Pharma and Sanofi, Sanofi is responsible for the development, manufacturing, and commercialization of products resulting from the collaboration, including IPH6101/SAR'579 and IPH6401/SAR'514. Innate Pharma is eligible to receive milestone payments of up to €400 million, as well as royalties on net sales, as part of the agreement.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva